✉ Email this page to a colleague
« Back to Dashboard
GDC-0810 is an investigational drug.
There have been 184 clinical trials for GDC-0810. The most recent clinical trial was a Phase 3 trial, which was initiated on January 8th 2013.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are nine US patents protecting this investigational drug and one hundred and forty-two international patents.
Recent Clinical Trials for GDC-0810
|Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1|
|Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL||Kazia Therapeutics Limited||Phase 2|
Top disease conditions for GDC-0810
Top clinical trial sponsors for GDC-0810
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GDC-0810||See Plans and Pricing||Estrogen receptor mutations and uses thereof||FOUNDATION MEDICINE, INC. (Cambridge, MA)||See Plans and Pricing|
|GDC-0810||See Plans and Pricing||Heteroaryl estrogen receptor modulators and uses thereof||Genentech, Inc. (South San Francisco, CA)||See Plans and Pricing|
|GDC-0810||See Plans and Pricing||Polymorphic forms of RAD1901-2HCl||RADIUS PHARMACEUTICALS, INC. (Waltham, MA)||See Plans and Pricing|
|GDC-0810||See Plans and Pricing||Soft gelatin capsule formulation||KaNDy Therapeutics Limited (Stevenage Herts, GB)||See Plans and Pricing|
|GDC-0810||See Plans and Pricing||Estrogen receptor modulators and uses thereof||Aragon Pharmaceuticals, Inc. (San Diego, CA)||See Plans and Pricing|
|GDC-0810||See Plans and Pricing||Estrogen receptor modulators and uses thereof||Genentech, Inc. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GDC-0810||Australia||AU2014358850||2033-12-06||See Plans and Pricing|
|GDC-0810||Canada||CA2932106||2033-12-06||See Plans and Pricing|
|GDC-0810||China||CN105916501||2033-12-06||See Plans and Pricing|
|GDC-0810||European Patent Office||EP3089747||2033-12-06||See Plans and Pricing|
|GDC-0810||Hong Kong||HK1223557||2033-12-06||See Plans and Pricing|
|GDC-0810||Israel||IL245758||2033-12-06||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|